Chen Hubert C 4

What Happened

• Hubert C. Chen, Chief Medical Officer of Viking Therapeutics (VKTX), received a grant/award of 190,000 derivative shares (reported at $0.00) on June 1, 2026. The filing lists the transaction as an award/acquisition (derivative), not an open-market purchase or sale, so no cash changed hands in this report.

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-03 (appears timely).
• Reported amount: 190,000 shares; reported price: $0.00 (award/derivative).
• Vesting: 25% vested immediately; then 25% will vest on each one‑year anniversary of the grant date over the next three years (footnote F1).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Transaction code: A (grant/award/acquisition of derivative security).

Context

• This was an equity compensation award (derivative), common for executives as part of pay and retention, and does not by itself indicate a purchase or sale by the insider.
• The immediate 25% vesting means a portion becomes exercisable/owned right away; remaining shares vest over the next three years per the schedule.